SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR
Idiopathic thrombocytopenic purpura is a chronic autoimmune hematological disease caused by an increased destruction of platelets and associated thrombocytopenia, for the treatment of which the imported drug romiplostim is used. Сreation of the drug biosimilar provides a reduction in the cost of the...
Saved in:
Main Authors: | A. N. Afanasyeva, V. B. Saparova, D. D. Karal-Ogly, E. I. Mukhametzyanova, D. V. Kurkin, A. V. Kalatanova, I. E. Makarenko, A. L. Khokhlov, I. A. Lugovik |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2022-10-01
|
Series: | Фармация и фармакология (Пятигорск) |
Subjects: | |
Online Access: | https://www.pharmpharm.ru/jour/article/view/1165 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Thrombopoietin Receptor Agonists: Clinical Use and Evaluation of Treatment Efficacy
by: A. G. Solodovnikov, et al.
Published: (2020-12-01) -
CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS
by: E. A. Pyadushkina, et al.
Published: (2016-02-01) -
Management of patients with immune thrombocytopenia in the Moscow region
by: S. G. Zakharov, et al.
Published: (2022-11-01) -
Experience of 2<sup>nd</sup> line therapy with eltrombopag in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2023-09-01) -
Successful resection of intrahepatic cholangiocarcinoma with idiopathic thrombocytopenic purpura using thrombopoietin receptor agonist: a case report
by: Kouki Hoshino, et al.
Published: (2019-04-01)